US › Healthcare

AN2 Therapeutics Inc (ANTX)

US · Healthcare · Biotechnology

$5.94+6.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.0M
Profit YoY
+5.8%
EPS
$-0.29
EPS estimate
$-0.23

EPS came in at -0.29 against a street estimate of -0.23 — a miss of 26.1%.

Key statistics

Market cap
$201.0M
Forward P/E
0.0
P/B
2.36
Book value
$2.27
EPS (TTM)
$-1.10
52-week high
$6.91
52-week low
$1.00
50-day MA
$4.68
200-day MA
$2.80
Beta
-0.99

Analyst view

Analysts rate AN2 Therapeutics Inc a hold (1 buy, 1 hold, 1 sell out of 3) with an average price target of $9.00.

Shareholding

Insiders
18.99%
Institutions
71.03%

Largest institutional holders

FundStake
Vivo Capital, LLC8.76%
COMMODORE CAPITAL LP6.48%
Millennium Management LLC6.17%
Spruce Street Capital LP4.61%
Almitas Capital LLC4.11%
Vanguard Capital Management, LLC2.81%
Adage Capital Partners Gp LLC2.78%
Woodline Partners LP2.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for AN2 Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.